---
title: "Xolair (omalizumab) in allergic asthma: Pharmacology questions"
description: "Pharmacology questions on Xolair (omalizumab) in allergic asthma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism and Pharmacokinetics. Questions: How does Xolair work in asthma (mechanism of action)? How long does Xolair stay in your system (half-life)? What happens to IgE levels after starting or stopping Xolair? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/xolair--allergic-asthma/pharmacology"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Xolair (omalizumab) in allergic asthma: Pharmacology questions

Manufacturer: Genentech, Inc.; Novartis Pharmaceuticals Corporation  
Prescribing information: [Xolair](https://www.gene.com/download/pdf/xolair_prescribing.pdf)

Pharmacology questions that apply to every indication of Xolair are on [Xolair (omalizumab), all indications: Pharmacology](https://www.evicenter.com/medical-information/xolair/pharmacology).

## Mechanism

<a id="xolair-mechanism"></a>

### How does Xolair work in asthma (mechanism of action)?

> “Omalizumab inhibits the binding of IgE to the high-affinity IgE receptor (FcεRI) on the 
> surface of mast cells, basophils, and dendritic cells, resulting in FcεRI down-regulation on 
> these cells.   
> In allergic asthmatics, treatment with omalizumab inhibits IgE-mediated inflammation, as 
> evidenced by reduced blood and tissue eosinophils and reduced inflammatory mediators, 
> including IL-4, IL-5, and IL-13.”

Source: [XOLAIR: Prescribing information, page 27, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=27)

> “In clinical studies, serum free IgE levels were reduced in a dose-dependent manner within 1 hour following the first dose and maintained between doses”

Source: [XOLAIR: XOLAIR® (omalizumab) MOA | Allergic Asthma Treatment, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/about-xolair/mechanism-of-action.html#:~:text=In%20clinical%20studies%2C%20serum%20free,dose%20and%20maintained%20between%20doses)

> “>96% decrease in mean serum free IgE when XOLAIR was used atrecommended doses”

Source: [XOLAIR: XOLAIR® (omalizumab) MOA | Allergic Asthma Treatment, captured 2026-11-13](https://www.xolairhcp.com/allergic-asthma/about-xolair/mechanism-of-action.html#:~:text=%3E96%25%20decrease%20in%20mean%20serum,doses)

## Pharmacokinetics

<a id="xolair-half-life"></a>

### How long does Xolair stay in your system (half-life)?

> “In asthma patients omalizumab serum elimination 
> half-life averaged 26 days, with apparent clearance averaging 2.4 ± 1.1 mL/kg/day.  
> Doubling body weight approximately doubled apparent clearance.”

Source: [XOLAIR: Prescribing information, page 29, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=29)

> “After SC administration, omalizumab was absorbed with an average absolute bioavailability 
> of 62%.  Following a single SC dose in adult and adolescent patients with asthma, 
> omalizumab was absorbed slowly, reaching peak serum concentrations after an average of 7–
> 8 days.”

Source: [XOLAIR: Prescribing information, page 28, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=28)

<a id="xolair-ige-levels-after-treatment"></a>

### What happens to IgE levels after starting or stopping Xolair?

> “Serum total IgE levels (i.e., bound and 
> unbound) increased after the first dose due to the formation of omalizumab:IgE complexes, 
> which have a slower elimination rate compared with free IgE.  At 16 weeks after the first 
> dose, average serum total IgE levels were five-fold higher compared with pre-treatment when 
> using standard assays.  After discontinuation of XOLAIR dosing, the XOLAIR-induced”

Source: [XOLAIR: Prescribing information, page 27, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=27)

> “increase in total IgE and decrease in free IgE were reversible, with no observed rebound in 
> IgE levels after drug washout.  Total IgE levels did not return to pre-treatment levels for up 
> to one year after discontinuation of XOLAIR.”

Source: [XOLAIR: Prescribing information, page 28, captured 2026-11-13](https://www.gene.com/download/pdf/xolair_prescribing.pdf#page=28)

## Related pages
- [Medical information: Xolair (omalizumab): Allergic asthma](https://www.evicenter.com/medical-information/xolair--allergic-asthma)
- [Indication](https://www.evicenter.com/medical-information/xolair--allergic-asthma/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/xolair--allergic-asthma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/xolair--allergic-asthma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/xolair--allergic-asthma/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/xolair--allergic-asthma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/xolair--allergic-asthma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/xolair--allergic-asthma/access-and-coverage)
